Lesson plan
Tabelecleucel
Tabelecleucel, sold under the brand name Ebvallo, is a medication used for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Tabelecleucel is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in a human leukocyte antigen (HLA)-restricted manner. It is made of cells of the immune system called T-cells that have been taken from a donor (allogeneic) and are then mixed with EBV-infected B-cells from the same donor. The most common side effects include fever, diarrhea, fatigue, nausea (feeling sick), anemia (low red blood cell count), reduced appetite, hyponatremia (low sodium levels in the blood), abdominal pain, low white blood cell count, including neutrophils (white blood cells that fight infections), elevated blood levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase (indicators of potential liver damage), constipation, hypoxia (low blood oxygen levels), dehydration, hypotension (low blood pressure), nasal congestion, and rash. Tabelecleucel was approved for medical use in the European Union in December 2022.
Article summary
Tabelecleucel, sold under the brand name Ebvallo, is a medication used for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Tabelecleucel is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in a human leukocyte antigen (HLA)-restricted manner. It is made of cells of the immune system called T-cells that have been taken from a donor (allogeneic) and are then mixed with EBV-infected B-cells from the same donor. The most common side effects include fever, diarrhea, fatigue, nausea (feeling sick), anemia (low red blood cell count), reduced appetite, hyponatremia (low sodium levels in the blood), abdominal pain, low white blood cell count, including neutrophils (white blood cells that fight infections), elevated blood levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase (indicators of potential liver damage), constipation, hypoxia (low blood oxygen levels), dehydration, hypotension (low blood pressure), nasal congestion, and rash. Tabelecleucel was approved for medical use in the European Union in December 2022.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.